Analyst: Ebola order has positive signal value for Bavarian's investors
The recent USD 28m order that Janssen has placed with Bavarian hints at the fact that ebola outbreaks will keep occurring in the future, according to Danish bank analyst Søren Løntoft Hansen.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
The new bulk vaccine order placed with Bavarian Nordic for the ebola vaccine to which Johnson & Johnson holds the rights has positive signal value for investors, according to Senior Equity Analyst Søren Løntoft Hansen from the Danish bank Sydbank, following Bavarian Nordic's Tuesday announcement that the order amounted to USD 28m.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic's CBO quits
For subscribers
